Glycemic Control Assessment in the Dialysis Patient: Is Glycated Albumin the Answer?

Molitch, Mark E.

doi:10.1159/000485844

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several HbA1c alternatives have been proposed for the dialysis population. Among the most investigated variables are serum glycated albumin and the use of devices that continuously monitor glucose levels . In agreement with Ito et al, who evaluated vildagliptin in combination with other oral antidiabetes agents, we have herein reported a significant decrease in serum glycated albumin in patients under vildagliptin and insulin.…”

Section: Discussionsupporting

confidence: 90%

“…Moreover, the hormonal dysregulation of hepatic glucose production in ESRD patients may further increase the risk of hypoglycaemic episodes. Measurements of blood glucose levels, HbA1c, and, less often, glycated albumin are employed as markers of glycaemic control in haemodialysed patients with diabetes. However, single measurements of HbA1c and random blood glucose values are not always instrumental in helping a greater proportion of ESRD patients achieve long‐term metabolic control.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study

Munch¹,

Meyer²,

Hannedouche³

et al. 2020

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim: To evaluate the effect of adding the dipeptidyl-peptidase-4 inhibitor vildagliptin to insulin on the glycaemic control of patients with type 2 diabetes undergoing haemodialysis.Methods: Overall, 65 insulin-treated patients with type 2 diabetes undergoing haemodialysis (HbA1c: 7.3% ± 1.1%; age: 70.5 ± 8.5 years) were randomized (1:1) either to receive vildagliptin 50 mg/day in addition to insulin (vildagliptin-insulin group) or to pursue their usual insulin regimen (insulin-only group). Continuous glucose monitoring (CGM) was performed for 48 ± 6 hours at baseline and at week 12. The primary This study was supported by Novartis Inc., France.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study

Munch¹,

Meyer²,

Hannedouche³

et al. 2020

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…9 It can reverse the glomerular hypertrophy and hyperfilteration that involved in the pathogenesis of diabetic nephropathy and reduces the incidence of newly-onset microalbuminuria, on the other hand, progression of overt nephropathy can be stabilized or attenuated via strict glycemic control; therefore monitoring and assessment of glycemic control in diabetic patients with renal disease on hemodialysis is so important factor in assessment of the progression of disease and to control the outcomes. 10 The current study included 50 diabetic Iraqi patients on hemodialysis with a mean age of 54. in diabetic patients compared to non-diabetic. 11 Among our studied group, males were relatively dominant with a male to female ratio of 1.33 to one.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of plasma glucose control in diabetic patients on hemodialysis a single center study

2022

View full text Add to dashboard Cite

Objectives: The aim of study is to evaluate plasma glucose control in diabetic patient on hemodialysis by measure plasma glycated albumin and HbA1c and correlate them with parameters like serum electrolytes blood urea, serum creatinine, hemoglobin, serum albumin, total serum bilirubin, serum uric acid, parathyroid hormone, serum ferritin; to evaluate the effects of these parameters on the level of diabetic control. Methods: This is a cross sectional study which included type 2 diabetic patients on hemodialysis these patients are currently undergoing hemodialysis and are on hemodialysis for more than three months. Total 50 type 2 diabetic patients on hemodialysis; between ages of 47-62 years of either gender were selected randomly and comparison done between the effect of different factors on HbA1c and glycated albumin. Results: There were 50 patients enrolled in this study with a mean age of 54.5 ± 4.7 (range: 47 – 62) years. Males represented 58% (29 patients) while female represent 42% (21 patients) of the studied group with male to female ratio of 1.38 to one. The duration of diabetes (DM) ranged 4 – 20 years and two thirds of the cases had duration of 15 years or less. Regarding the treatment of DM, 35 patients (70%) were on soluble insulin while 15 patients neither receive insulin nor oral antidiabetic agent and their treatment was off. poor glycemic control was significantly associated with younger age, patients aged < 50 years were more frequent among the poor glycemic. good glycemic control had significantly lower HbA1C% level. Conclusion: Most of our diabetic patient on HD has controlled diabetes reflected by the level of HbA1c and GA. Serum ferritin levels is positively correlate with HbA1c levels in diabetic patient on hemodialysis which suggests that serum ferritin levels can be a marker of glycemic control in type 2 DM.

show abstract

Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes

Hahr

Molitch

2020

Textbook of Cardiorenal Medicine

View full text Add to dashboard Cite

Glycemic Control Assessment in the Dialysis Patient: Is Glycated Albumin the Answer?

Cited by 4 publications

References 21 publications

Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study

Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study

Evaluation of plasma glucose control in diabetic patients on hemodialysis a single center study

Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes

Contact Info

Product

Resources

About